Innovative
Therapeutics for
Better Health
Because Life
Shouldn't Have to
Wait for Migraines
Our Lead Product Candidate
STS101
Dihydroergotamine (DHE) Nasal Powder
Learn More
Press Releases
Oct 31, 2024
Satsuma Pharmaceuticals and SNBL Resubmits the New Drug Application for STS101 (Dihydroergotamine Nasal Powder) for the Acute Treatment of Migraine With or Without Aura
Read More
Oct 08, 2024
Satsuma Pharmaceuticals and SNBL Announce Publication of STS101 (Dihydroergotamine Nasal Powder) Pivotal Phase 3 ASCEND Study in CNS Drugs
Read More